Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Otsuka’s 1st Half Pharma Sales Rise 7.6% as 4 Global Brands Fare Well
Otsuka Holdings’half-year pharma sales grew 7.6% year on year thanks to buoyant revenues from four global brands including the antipsychotic agents Abilify Maintena (aripiprazole) and Rexulti/Rxulti (brexpiprazole). In January-June, the company generated sales of 471,773 million yen in its pharmaceutical…
To read the full story
Related Article
- Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
August 2, 2024
- Otsuka’s Q1 Pharma Sales Zoom 16.2% on Global Brands
May 1, 2024
- Otsuka’s 2023 Pharma Sales Climb 20% on 4 Global Brands
February 15, 2024
- Otsuka’s Pharma H1 Sales Zoom 20% as Global Brands Fare Well
August 1, 2023
- Otsuka’s Q1 Pharma Sales Climb 20.3% Buoyed by Global Products
May 15, 2023
- Otsuka’s Pharma Sales Up 16.4% in 2022 on Global Brands, Hits 2023 Target 1 Year Earlier
February 15, 2023
- Otsuka Logs 13.6% Growth in 9-Month Pharma Sales on 4 Global Products
November 1, 2022
- Otsuka’s Q1 Pharma Sales Up 11.9% Driven by Global Brands, Profits Dip on FDA Vadadustat Snub
May 16, 2022
- Otsuka’s 4 Global Brands Fare Well to Hit 2023 Target 2 Years Earlier
February 14, 2022
- Otsuka’s 4 Global Brands Likely to Hit 480 Billion Yen, 2 Years Earlier
August 10, 2021
- Otsuka’s Q1 Pharma Sales Down 5.0% on Japan Dip, 4 Global Brands Grow
May 14, 2021
- Otsuka’s Pharma Sales Up 3.3% in 2020 Driven by 4 Global Brands
February 15, 2021
- Otsuka’s Pharma Sales Grow 6.3% in January-September on Global Brands
November 16, 2020
- Otsuka’s Q1 Pharma Sales Surge 13% on Global Brands
May 29, 2020
- Otsuka’s Pharma Sales Surge as Tolvaptan Grows Six-Fold in North America
February 17, 2020
BUSINESS
- Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
- COVID as a Lesson, Pfizer Exec Urges Govt to Draft Emergency Safety Management Guidelines
November 22, 2024
- Kyowa Kirin, Kura Form Global Collab on Leukemia Drug
November 22, 2024
- Alloy Inks Cell Therapy Deal with Takeda, Japan Outpost to Launch by Month-End
November 22, 2024
- Pfizer, Hokkaido Forge Comprehensive Healthcare Partnership
November 22, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…